Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
News
Market Highlights: Fed projects one more rate hike, Klaviyo’s debut, and 5 ASX small caps to watch
Health & Biotech
ScoPo’s Powerplays: Mesoblast sinks Health sector, and how to live 24 years longer
News
CLOSING BELL: Shopping centres, diggers and banks drive local market +0.65% against overseas tide
Health & Biotech
ASX Health stocks: INOVIQ soars 44pc on clinical data for breast cancer test
News
CLOSING BELL: Local markets climbed 0.86% today, but those sods at the RBA want you out of a job
News
CLOSING BELL: A massive win for Zelira’s new pain drug has polished an absolute turd of a day
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall as investors fail to reward good news
Health & Biotech
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Health & Biotech
ASX Health Stocks: Patrys, Immutep jump after reports show drugs well tolerated
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise, Immutep surges 46pc on trial results
Health & Biotech
ASX Health Stocks: FDA approves Imugene’s Phase 1 trial; Noxopharm says it can fight skin disease
News
ASX Small Caps Market Wrap: What shifty trick have those jokesters at Qantas come up with this morning?
Health & Biotech
ASX Health Stocks: Rhythym Bio skyrockets 70pc after being granted UK CA Mark
News
Market Highlights: China to benefit from a possible US default, and 5 ASX small caps to watch today
News
Market Highlights: JPMorgan bids for First Republic, Exxon’s record profit, and 5 ASX small caps to watch on Monday
News
Market Highlights: New banking crisis as First Republic seeks a lifeline; and 5 ASX small caps to watch today
News
